Periomics Care LLC
New York, NY
- UEI
- FLLTVXQCQ426
- CAGE
- 80NS0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 201 E 28th St #11-a, New York, NY 10016, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Greenmark Biomedical Inc. | East Lansing, MI | — |
| The Forsyth Institute | Somerville, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Soligenix, Inc. | Princeton, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Privo Technologies, Inc. | Peabody, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biovinc, LLC | Pasadena, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Periomics Care LLC is a biotechnology company based in New York focused on developing novel oral formulations for treating periodontal disease. It was established with the goal of commercializing a patented oral gel formulation called POC7A, which targets the succinate receptor SUCNR1 to reduce inflammation, alter the subgingival microbiome, and prevent bone loss associated with periodontal disease.
Through federal grant awards from the National Institutes of Health (NIH), Periomics Care LLC has received significant funding to advance the development of POC7A. In 2019, the company was awarded a $3.2 million Phase II STTR grant from the National Institute of Dental and Craniofacial Research (NIDCR) to scale up the synthesis and formulation of POC7A, conduct pharmacokinetic and toxicity studies in beagle dogs, and validate the efficacy of POC7A in a ligature-induced non-human primate model of periodontal disease. Additionally, the company received a $399,752 grant from the National Cancer Institute (NCI) in 2020 to investigate the modulation of the gut microbiome to enhance the efficacy of immunotherapy in pancreatic adenocarcinoma. Periomics Care LLC has also been awarded a $221,537 Phase I grant from NIDCR for the initial development of POC7A as a novel remedy for periodontal bone loss.
Quick answers
Is Periomics Care LLC registered in SAM.gov?
Yes. Periomics Care LLC's SAM.gov registration is active through October 21, 2027.
What is Periomics Care LLC's most recent federal award?
Periomics Care LLC's most recent federal grant award is Zinc nanocrystals from zinc tetraammine fluoride for caries arrest and remineralization (R41DE034627), from National Institute of Dental and Craniofacial Research (NIH), on August 6, 2025.
On GovTribe
See Periomics Care LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors